Kagiyama Shuntaro, Matsumura Kiyoshi, Goto Kenichi, Otsubo Toshio, Iida Mitsuo
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Regul Pept. 2010 Feb 25;160(1-3):133-9. doi: 10.1016/j.regpep.2009.12.002. Epub 2009 Dec 5.
Large clinical trials have shown that mineralocorticoid receptor (MR) antagonists improve cardiovascular or total mortality in patients with heart failure or myocardial infarction even though the patients were taking angiotensin-converting enzyme inhibitors or angiotensin II receptor (AT1R) antagonists. We previously reported that cardiac fibrosis induced by aldosterone and salt (Ald-NaCl) was exaggerated in AT1aR knockout mice (AT1aR-KOs). As the association of Rho kinase and oxidative stress was reported in Ald-NaCl-induced hypertension of rats, we investigated the effects of an MR antagonist (eplerenone) and a Rho kinase inhibitor (fasudil) on Ald-NaCl-induced cardiac fibrosis in AT1aR-KOs. AT1aR-KOs were administered aldosterone (0.15 microg/h) subcutaneously using an osmotic minipump and were provided with 1% NaCl drinking water for 4weeks. AT1aR-KOs receiving Ald-NaCl were treated with a low (30 mg/kg/day) or high (100mg/kg/day) dose of eplerenone or a fasudil (100mg/kg/day). Systolic blood pressure (SBP), left ventricular weight/body weight (LVW/BW), histological examination and cardiac gene expression were evaluated on day 28. Ald-NaCl treatment caused increases in SBP and LVW/BW in AT1aR-KOs, and eplerenone dose-dependently decreased SBP, LVW/BW and cardiac fibrosis. Fasudil decreased LVW/BW and cardiac fibrosis without affecting SBP. The expressions of connecting tissue growth factor (CTGF) and nicotinamide adenine dinucleotide phosphate (NADPH) components (p22phox, p47phox and p67phox) were increased in Ald-NaCl-treated AT1aR-KOs, and eplerenone or fasudil decreased the expression of CTGF and NADPH components. Phosphorylated ERM (a marker of the phosphorylation of Rho kinase) was increased in Ald-NaCl-treated AT1aR-KOs and was decreased by eplerenone. Nitrotyrosine and 4-hydroxy-2-nonenal, which indicate tissue damage via oxidative stress, were increased in AT1aR-KO and were apparently attenuated by eplerenone or fasudil. These results suggested that the Rho kinase pathway was activated to induce cardiac fibrosis by Ald-NaCl via MR in AT1aR-KOs. A Rho kinase inhibitor as well as eplerenone might be useful for cardiac damage by Ald-NaCl.
大型临床试验表明,盐皮质激素受体(MR)拮抗剂可改善心力衰竭或心肌梗死患者的心血管疾病或全因死亡率,即便这些患者正在服用血管紧张素转换酶抑制剂或血管紧张素II受体(AT1R)拮抗剂。我们之前报道过,在AT1aR基因敲除小鼠(AT1aR-KO)中,醛固酮和盐(Ald-NaCl)诱导的心脏纤维化会加剧。由于有报道称Rho激酶与氧化应激在Ald-NaCl诱导的大鼠高血压中存在关联,我们研究了一种MR拮抗剂(依普利酮)和一种Rho激酶抑制剂(法舒地尔)对Ald-NaCl诱导的AT1aR-KO心脏纤维化的影响。使用渗透微型泵给AT1aR-KO皮下注射醛固酮(0.15微克/小时),并提供1% NaCl饮用水,持续4周。接受Ald-NaCl处理的AT1aR-KO用低剂量(30毫克/千克/天)或高剂量(100毫克/千克/天)的依普利酮或法舒地尔(100毫克/千克/天)进行治疗。在第28天评估收缩压(SBP)、左心室重量/体重(LVW/BW)、组织学检查和心脏基因表达。Ald-NaCl处理使AT1aR-KO的SBP和LVW/BW升高,依普利酮剂量依赖性地降低SBP、LVW/BW和心脏纤维化。法舒地尔降低LVW/BW和心脏纤维化,但不影响SBP。在接受Ald-NaCl处理的AT1aR-KO中,结缔组织生长因子(CTGF)和烟酰胺腺嘌呤二核苷酸磷酸(NADPH)成分(p22phox、p47phox和p67phox)的表达增加,依普利酮或法舒地尔降低了CTGF和NADPH成分的表达。在接受Ald-NaCl处理的AT1aR-KO中,磷酸化的ERM(Rho激酶磷酸化的标志物)增加,依普利酮使其降低。硝基酪氨酸和4-羟基-2-壬烯醛(通过氧化应激指示组织损伤)在AT1aR-KO中增加,依普利酮或法舒地尔明显使其减弱。这些结果表明,在AT1aR-KO中,Rho激酶途径通过Ald-NaCl经MR被激活以诱导心脏纤维化。Rho激酶抑制剂以及依普利酮可能对Ald-NaCl所致的心脏损伤有用。